Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.
The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90% of the isolates tested were inhibited [MIC(90)s], <or=1 microg/ml). In addition, it was also very potent against most members of the Enterobacteriaceae, with most MIC(90)s being <or=2 microg/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomonas maltophilia are included in the in vitro spectrum of tigecycline activity.
Milatovic
D
D
Eijkman-Winkler Institute for Medical Microbiology, Utrecht, The Netherlands. d.milatovic@azu.nl
Schmitz
F-J
FJ
Verhoef
J
J
Fluit
A C
AC
D005060:Europe; D006095:Gram-Positive Cocci / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000078304:Tigecycline
D000078304:Tigecycline; D008911:Minocycline